We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Read MoreHide Full Article
Key Takeaways
KROS' investment case centers on rinvatercept as revenue visibility remains limited without product sales.
KROS expects initial phase II rinvatercept data in DMD in the first half of 2027.
KROS' premium valuation and clinical risks leave limited room for execution missteps.
Keros Therapeutics (KROS - Free Report) reported a second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. Revenues fell to zero from $18.2 million a year earlier.
The investment case now rests heavily on rinvatercept, while uneven collaboration income, clinical execution risk and a premium sales multiple limit near-term visibility. The question is whether the pipeline opportunity justifies taking on those risks today.
KROS Faces a Revenue Visibility Problem
Keros has no marketed products and therefore no recurring product revenues. First-half 2026 revenues were just $0.37 million and came entirely from service and other revenues, with no licensing revenues recognized during the period.
That is a sharp contrast with 2025, when revenues reached $244.1 million, including $205.4 million of license revenues tied largely to the Takeda agreement for elritercept. The timing of milestones and service payments can make quarterly results volatile, leaving investors with limited visibility into a repeatable top-line base.
Keros Cash Runway Buys Time for Rinvatercept
Cash and cash equivalents totaled $257.6 million at June 30, 2026, down from $281.5 million at March 31. Management expects existing resources to fund operating expenses and capital expenditure requirements into the first half of 2028.
The Takeda partnership also reduces some development burden because elritercept-related costs have transitioned to Takeda. Still, rinvatercept is now Keros' main internal development focus, and broader clinical activity could raise spending over time, making cash usage an important metric to watch.
Year to date, Keros shares have plunged 46.8% against the industry’s 11.1% growth.
Image Source: Zacks Investment Research
KROS Pipeline Upside Centers on Rinvatercept
Keros initiated a phase II study of rinvatercept in Duchenne muscular dystrophy in the third quarter of 2026 and expects initial data in the first half of 2027. Phase I findings showed increases in muscle mass and bone density, reduced fat and no serious adverse events.
The company also plans regulatory discussions in the second half of 2026 on a potential phase II study in amyotrophic lateral sclerosis. Positive development progress could broaden rinvatercept's opportunity, but the growing concentration on one lead asset also increases the impact of any clinical or timeline setback.
Keros Valuation Leaves Little Room for Missteps
KROS trades at 37.1X forward 12-month sales, compared with 1.9X for its Zacks sub-industry and 2.2X for its sector. Shares have also fallen 45.8% year to date, versus an 11.1% gain for the sub-industry.
Competition adds to the execution bar. Sarepta Therapeutics (SRPT - Free Report) has an established Duchenne muscular dystrophy franchise that includes ELEVIDYS and exon-skipping therapies. PTC Therapeutics (PTCT - Free Report) markets Emflaza in the United States for Duchenne muscular dystrophy patients two years and older, giving Keros established competitors as it advances rinvatercept.
KROS Signals Still Point to Caution
KROS offers meaningful clinical optionality, but zero second-quarter revenues, dependence on irregular collaboration income and reliance on rinvatercept make the risk-reward profile difficult to endorse aggressively at the current stage. The existing cash runway provides time for development, while 2027 DMD data represent an important future checkpoint.
The stock currently carries a Zacks Rank #3 (Hold), which indicates a neutral short-term outlook rather than a clear buy signal. KROS also has a VGM Score of F, Value Score of F, Growth Score of C and Momentum Score of D. Those Style Scores point to weak value and momentum characteristics and a middling growth profile, reinforcing the case for patience while clinical execution and revenue visibility develop. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Key Takeaways
Keros Therapeutics (KROS - Free Report) reported a second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. Revenues fell to zero from $18.2 million a year earlier.
The investment case now rests heavily on rinvatercept, while uneven collaboration income, clinical execution risk and a premium sales multiple limit near-term visibility. The question is whether the pipeline opportunity justifies taking on those risks today.
KROS Faces a Revenue Visibility Problem
Keros has no marketed products and therefore no recurring product revenues. First-half 2026 revenues were just $0.37 million and came entirely from service and other revenues, with no licensing revenues recognized during the period.
That is a sharp contrast with 2025, when revenues reached $244.1 million, including $205.4 million of license revenues tied largely to the Takeda agreement for elritercept. The timing of milestones and service payments can make quarterly results volatile, leaving investors with limited visibility into a repeatable top-line base.
Keros Cash Runway Buys Time for Rinvatercept
Cash and cash equivalents totaled $257.6 million at June 30, 2026, down from $281.5 million at March 31. Management expects existing resources to fund operating expenses and capital expenditure requirements into the first half of 2028.
The Takeda partnership also reduces some development burden because elritercept-related costs have transitioned to Takeda. Still, rinvatercept is now Keros' main internal development focus, and broader clinical activity could raise spending over time, making cash usage an important metric to watch.
Year to date, Keros shares have plunged 46.8% against the industry’s 11.1% growth.
Image Source: Zacks Investment Research
KROS Pipeline Upside Centers on Rinvatercept
Keros initiated a phase II study of rinvatercept in Duchenne muscular dystrophy in the third quarter of 2026 and expects initial data in the first half of 2027. Phase I findings showed increases in muscle mass and bone density, reduced fat and no serious adverse events.
The company also plans regulatory discussions in the second half of 2026 on a potential phase II study in amyotrophic lateral sclerosis. Positive development progress could broaden rinvatercept's opportunity, but the growing concentration on one lead asset also increases the impact of any clinical or timeline setback.
Keros Valuation Leaves Little Room for Missteps
KROS trades at 37.1X forward 12-month sales, compared with 1.9X for its Zacks sub-industry and 2.2X for its sector. Shares have also fallen 45.8% year to date, versus an 11.1% gain for the sub-industry.
Competition adds to the execution bar. Sarepta Therapeutics (SRPT - Free Report) has an established Duchenne muscular dystrophy franchise that includes ELEVIDYS and exon-skipping therapies. PTC Therapeutics (PTCT - Free Report) markets Emflaza in the United States for Duchenne muscular dystrophy patients two years and older, giving Keros established competitors as it advances rinvatercept.
KROS Signals Still Point to Caution
KROS offers meaningful clinical optionality, but zero second-quarter revenues, dependence on irregular collaboration income and reliance on rinvatercept make the risk-reward profile difficult to endorse aggressively at the current stage. The existing cash runway provides time for development, while 2027 DMD data represent an important future checkpoint.
The stock currently carries a Zacks Rank #3 (Hold), which indicates a neutral short-term outlook rather than a clear buy signal. KROS also has a VGM Score of F, Value Score of F, Growth Score of C and Momentum Score of D. Those Style Scores point to weak value and momentum characteristics and a middling growth profile, reinforcing the case for patience while clinical execution and revenue visibility develop. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.